German Parliament Considers Lowering Mandatory Drug Rebate Level
This article was originally published in The Pink Sheet Daily
The German Upper House has proposed reducing the obligatory rebate manufacturers of original drug products must give health insurers and closing a loophole in the law on generic drug discount contracts.
You may also be interested in...
Germany’s pharma industry is trying to force the government to reveal the decision-making process that led it to uphold the drug rebate and price freeze there, in the hope of avoiding fresh burdens in the future.
The updated German Pharmaceutical Act will ensure that drug prices negotiated there between pharmaceutical manufacturers and health insurers will remain hidden from public view, as Germany’s government seeks to avoid a pan-European drug price crash.
The decision by the German pharmaceutical arbitration committee to include countries such as Greece in a final pricing mechanism will cut German prices and may have a Europe-wide effect.